3068378-51-5
Chemical Structure
PLK1-IN-16
- CAS No.: 3068378-51-5
- Formula:C26H34N6O4S
- Molecular Weight:526.65
InChIKey: BOOZLJZTOBHOEV-HXUWFJFHSA-N
SMILES: O=S(N1C2=CC(OC)=C(NC3=NC=C4C(N(C5CCCC5)[C@H](CC)C(N4C)=O)=N3)C=C2CC1)(C6CC6)=O
Biological Activity: PLK1-IN-16 is a selective polo-like kinase 1 (PLK1) inhibitor with an IC50 of 0.25 nM. PLK1-IN-16 exhibits lower inhibitory potency against PLK2 and PLK3, induces G2 phase cell cycle arrest, induces apoptosis, and exhibits antiproliferative activity against tumor cells. PLK1-IN-16 can be stable under simulated gastric acid environmental conditions, and acceptable CYP 450 inhibition. PLK1-IN-16 can be used for the study of triple-negative breast cancer (TNBC), breast cancer, leukemia[1].
| Cat. No. | Product Name | Purity | Description | Pricing | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
PLK1-IN-16 | PLK1-IN-16 is a selective polo-like kinase 1 (PLK1) inhibitor with an IC50 of 0.25 nM. PLK1-IN-16 exhibits lower inhibitory potency against PLK2 and PLK3, induces G2 phase cell cycle arrest, induces apoptosis, and exhibits antiproliferative activity against tumor cells. PLK1-IN-16 can be stable under simulated gastric acid environmental conditions, and acceptable CYP 450 inhibition. PLK1-IN-16 can be used for the study of triple-negative breast cancer (TNBC), breast cancer, leukemia. | |||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
